Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 9/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8010587 | 0.89 | HDAC1 (0.43) | TAS2R8FAAHMCHR1HTR2ASLC6A4 | |
| SCHEMBL8010593 | 0.85 | TAS2R8 (0.44) | TAS2R8FAAHHTR2ASLC6A4 | |
| SCHEMBL8023307 | 0.85 | TAS2R8 (0.47) | TAS2R8FAAHHCRTR1HCRTR2SLC6A4 | |
| SCHEMBL8010610 | 0.84 | TAS2R8 (0.42) | TAS2R8FAAHHCRTR1HCRTR2HTR2A | |
| SCHEMBL8027024 | 0.84 | AR (0.43) | TAS2R8MCHR1 | |
| SCHEMBL12873219 | 0.84 | HTR2A (0.43) | TAS2R8MCHR1HTR2ASLC6A4 | |
| SCHEMBL8016883 | 0.84 | HTR2A (0.43) | TAS2R8FAAHMCHR1HTR2ASLC6A4 | |
| SCHEMBL2215663 | 0.84 | AR (0.47) | TAS2R8FAAHMCHR1HTR2ASLC6A4 | |
| SCHEMBL12873244 | 0.84 | HDAC1 (0.48) | TAS2R8FAAHHCRTR1HCRTR2HTR2A | |
| SCHEMBL8013213 | 0.83 | TAS2R8 (0.43) | TAS2R8FAAHMCHR1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046185-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | TAS2R8 318/4885FAAH 1395/4885MCHR1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.